VEGFA and neoplasm: Decreasing VEGF levels by bevacizumab is known to block angiogenesis, transiently normalize tumor vessels, sensitize tumors to radiotherapy and chemotherapy, improve tumor oxygenation and decrease interstitial fluid pressure, as well as restore delivery of drugs into the tumor [15, 30].